Medium Evidence Drugs
Candidates worth investigating with additional research
Evidence Standards
| Level | Definition | Clinical Significance |
|---|---|---|
| L3 | Phase 1/2 trials or observational studies | Preliminary support, requires more research |
Drug List
L3 Level (45 drugs)
| Drug Name | Predictions | Link |
|---|---|---|
| Acetaminophen | 1 | View Report |
| Acetic Acid | 9 | View Report |
| Acetylsalicylic Acid | 9 | View Report |
| Acitretin | 4 | View Report |
| Albendazole | 5 | View Report |
| Alprazolam | 3 | View Report |
| Amoxicillin | 8 | View Report |
| Bumetanide | 1 | View Report |
| Cabergoline | 5 | View Report |
| Calcipotriol | 10 | View Report |
| Captopril | 4 | View Report |
| Cefuroxime | 10 | View Report |
| Cephalexin | 5 | View Report |
| Chlordiazepoxide | 10 | View Report |
| Ciprofloxacin | 5 | View Report |
| Dupilumab | 10 | View Report |
| Eptinezumab | 1 | View Report |
| Estriol | 1 | View Report |
| Etanercept | 6 | View Report |
| Fenofibrate | 5 | View Report |
| Hydroxyurea | 10 | View Report |
| Imiquimod | 10 | View Report |
| Ketoconazole | 5 | View Report |
| Lacosamide | 10 | View Report |
| Loratadine | 5 | View Report |
| Lovastatin | 6 | View Report |
| Magnesium Trisilicate | 5 | View Report |
| Medroxyprogesterone Acetate | 5 | View Report |
| Meropenem | 10 | View Report |
| Midazolam | 1 | View Report |
| Mycophenolic Acid | 10 | View Report |
| Nitroglycerin | 5 | View Report |
| Ofloxacin | 5 | View Report |
| Oxcarbazepine | 10 | View Report |
| Potassium Citrate | 10 | View Report |
| Progesterone | 5 | View Report |
| Ramipril | 10 | View Report |
| Rifampicin | 10 | View Report |
| Rilpivirine | 5 | View Report |
| Risperidone | 5 | View Report |
| Romiplostim | 10 | View Report |
| Sofosbuvir | 8 | View Report |
| Teriparatide | 10 | View Report |
| Tocilizumab | 10 | View Report |
| Tryptophan | 8 | View Report |
What L3 Evidence Means
L3 level indicates:
- Early-stage trials: Phase 1 or Phase 2 studies exist
- Observational data: Cohort or case-control studies available
- Mechanism support: Preclinical evidence supports the hypothesis
- Potential value: Worth investigating but needs validation
Recommended Actions for L3 Candidates
- Review existing literature for mechanism of action
- Monitor ongoing trials for results
- Consider pilot studies if resources available
- Wait for Phase 3 data before clinical implementation
Transition to Higher Evidence
L3 drugs can be upgraded to L2 or L1 when:
- Phase 2/3 trial results are published
- Systematic reviews are completed
- Multiple independent studies confirm findings
Disclaimer
Drug repurposing predictions are for research purposes only. L3 evidence indicates preliminary support only. Clinical application requires further validation.
Drug repurposing predictions are for research purposes only. L3 evidence indicates preliminary support only. Clinical application requires further validation.